Tamer, F. And Avci, E. 2020. Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study. CROATIAN MEDICAL JOURNAL , vol.61, no.4 , 333-337.

Tamer, F., & Avci, E., (2020). Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study. CROATIAN MEDICAL JOURNAL , vol.61, no.4, 333-337.

Tamer, FUNDA, And Emine Avci. "Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study," CROATIAN MEDICAL JOURNAL , vol.61, no.4, 333-337, 2020

Tamer, FUNDA And Avci, Emine. "Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study." CROATIAN MEDICAL JOURNAL , vol.61, no.4, pp.333-337, 2020

Tamer, F. And Avci, E. (2020) . "Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study." CROATIAN MEDICAL JOURNAL , vol.61, no.4, pp.333-337.

@article{article, author={FUNDA TAMER And author={Emine Avci}, title={Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study}, journal={CROATIAN MEDICAL JOURNAL}, year=2020, pages={333-337} }